Moderna (MRNA) Cash from Operations Growth (1y) (2019 - 2026)
Moderna (MRNA) Cash from Operations Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 158.60% |
| 10 | Moderna | 22.07 Bn | 16.87 Bn | -566.00 Mn | 39.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.25% |
| Dec 31, 2025 | 12.73% |
| Sep 30, 2025 | 45.91% |
| Jun 30, 2025 | 27.86% |
| Mar 31, 2025 | -4.85% |
| Dec 31, 2024 | 32.64% |
| Sep 30, 2024 | 2.12% |
| Jun 30, 2024 | -39.23% |
| Mar 31, 2024 | 19.27% |
| Dec 31, 2023 | -62.58% |
| Sep 30, 2023 | -734.92% |
| Jun 30, 2023 | -400.99% |
| Mar 31, 2023 | -144.34% |
| Dec 31, 2022 | -49.79% |
| Sep 30, 2022 | -92.31% |
| Jun 30, 2022 | -92.52% |
| Mar 31, 2022 | -7.00% |
| Dec 31, 2021 | 161.87% |
| Sep 30, 2021 | 266.85% |
| Jun 30, 2021 | 17,029.17% |